{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T22:36:26Z","timestamp":1784068586426,"version":"3.55.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.eururo.2018.09.020","type":"journal-article","created":{"date-parts":[[2018,9,29]],"date-time":"2018-09-29T13:01:35Z","timestamp":1538226095000},"page":"593-601","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["BOXIT\u2014A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK\/07\/004)"],"prefix":"10.1016","volume":"75","author":[{"given":"John D.","family":"Kelly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei Shen","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Porta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugh","family":"Mostafid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Huddart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Protheroe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Bogle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Blazeby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo","family":"Cresswell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Brough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeev","family":"Madaan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Andrews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare","family":"Cruickshank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Burnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Maynard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2018.09.020_bib0125","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1016\/j.eururo.2018.09.020_bib0130","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.eururo.2015.06.045","article-title":"EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1\u20133 years of maintenance bacillus Calmette-Guerin","volume":"69","author":"Cambier","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2018.09.020_bib0135","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ctrv.2016.05.002","article-title":"Management of non-muscle invasive bladder cancer: a comprehensive analysis of guidelines from the United States, Europe and Asia","volume":"47","author":"Tan","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.eururo.2018.09.020_bib0140","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","article-title":"Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials","volume":"168","author":"Sylvester","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2018.09.020_bib0145","first-page":"362","article-title":"Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells","volume":"58","author":"Sheng","year":"1998","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2018.09.020_bib0150","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1096\/fj.01-0299fje","article-title":"COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib","volume":"15","author":"Grosch","year":"2001","journal-title":"FASEB J"},{"key":"10.1016\/j.eururo.2018.09.020_bib0155","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1054\/bjoc.1999.1106","article-title":"Non-steroidal anti-inflammatory drugs and bladder cancer prevention","volume":"82","author":"Castelao","year":"2000","journal-title":"Br J Cancer"},{"key":"10.1016\/j.eururo.2018.09.020_bib0160","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S0090-4295(02)01909-X","article-title":"Association of cyclooxygenase-2 expression with prognosis of stage T1 grade 3 bladder cancer","volume":"60","author":"Kim","year":"2002","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2018.09.020_bib0165","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1158\/1940-6207.CAPR-11-0036","article-title":"A randomized controlled trial of celecoxib to prevent recurrence of nonmuscle-invasive bladder cancer","volume":"4","author":"Sabichi","year":"2011","journal-title":"Cancer Prev Res"},{"key":"10.1016\/j.eururo.2018.09.020_bib0170","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0302-2838(01)00026-4","article-title":"Guidelines on bladder cancer","volume":"41","author":"Oosterlinck","year":"2002","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2018.09.020_bib0175","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2018.09.020_bib0180","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.eururo.2014.02.034","article-title":"Validation and reliability testing of the EORTC QLQ-NMIBC24 questionnaire module to assess patient-reported outcomes in non-muscle-invasive bladder cancer","volume":"66","author":"Blazeby","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2018.09.020_bib0185","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0022-5347(17)34863-2","article-title":"Megadose vitamins in bladder cancer: a double-blind clinical trial","volume":"151","author":"Lamm","year":"1994","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2018.09.020_bib0190","doi-asserted-by":"crossref","first-page":"e45025","DOI":"10.1371\/journal.pone.0045025","article-title":"Cyclooxygenase-2 expression in bladder cancer and patient prognosis: results from a large clinical cohort and meta-analysis","volume":"7","author":"Czachorowski","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.eururo.2018.09.020_bib0195","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1161\/CIRCULATIONAHA.108.764530","article-title":"Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials","volume":"117","author":"Solomon","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.eururo.2018.09.020_bib0200","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1001\/jama.286.8.954","article-title":"Risk of cardiovascular events associated with selective COX-2 inhibitors","volume":"286","author":"Mukherjee","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2018.09.020_bib0205","first-page":"961","article-title":"Tumor cyclooxygenase 2-dependent suppression of dendritic cell function","volume":"9","author":"Sharma","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2018.09.020_bib0210","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/01.ju.0000161589.85869.ae","article-title":"Cyclooxygenase-2 inhibition: a potential mechanism for increasing the efficacy of bacillus Calmette-Guerin immunotherapy for bladder cancer","volume":"174","author":"Dovedi","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2018.09.020_bib0215","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1038\/sj.bjc.6601474","article-title":"Polarisation of a T-helper cell immune response by activation of dendritic cells with CpG-containing oligonucleotides: a potential therapeutic regime for bladder cancer immunotherapy","volume":"89","author":"Atkins","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.eururo.2018.09.020_bib0220","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nature13904","article-title":"MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer","volume":"515","author":"Powles","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.eururo.2018.09.020_bib0225","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.juro.2013.03.097","article-title":"The impact of intravesical gemcitabine and 1\/3 dose bacillus Calmette-Guerin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: results of a prospective, randomized, phase II trial","volume":"190","author":"Gontero","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2018.09.020_bib0230","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1056\/NEJMoa0801297","article-title":"Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome","volume":"359","author":"Burn","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2018.09.020_bib0235","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1056\/NEJMoa067208","article-title":"Aspirin and the risk of colorectal cancer in relation to the expression of COX-2","volume":"356","author":"Chan","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2018.09.020_bib0240","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S1470-2045(09)70035-X","article-title":"Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement","volume":"10","author":"Cuzick","year":"2009","journal-title":"Lancet Oncol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283818306833?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283818306833?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,4]],"date-time":"2019-04-04T20:55:22Z","timestamp":1554411322000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283818306833"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S0302283818306833"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2018.09.020","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"BOXIT\u2014A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK\/07\/004)","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2018.09.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}